Overview

Individual participation in this study will last approximately 48 months for participants who received AAV2-hAQP1 in Study MGT-AQP1-201 and at least 60 months for participants who receive AAV2-hAQP1 in Study MGT-AQP1-202.

Principal investigator

Henry Hoffman
Otolaryngology-Head & Nec
View other research studies by Henry Hoffman

Eligibility criteria

Inclusion Criteria:
*  Received study drug in Study MGT-AQP1-201

Exclusion Criteria:
*  Withdrew consent to participate in Study MGT-AQP1-201.
Show more

Participate in this trial

Are you interested in enrolling in this study? Learn more here.

I'm Interested In Participating

For Referring Providers

Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.

Contact the study coordinator

McLean Sunderland
319-384-8335
mclean-sunderland@uiowa.edu
Enroll your patient